Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer

Summary

Open label, single arm, dose-escalation phase I study in ambulatory patients receiving first line chemotherapy for metastatic breast cancer. The treatment comprises of the standard 6 cycles of weekly paclitaxel (80 mg/m² IV at D1, D8 and D15 of a 28 day cycle) and two EOC202 doses (6 and 30 mg SC at D2 and D16 of a 28 day cycle) for 6 cycles. After completion of the combined therapy, the patients can continue to receive up to 6 cycles of EOC202 maintenance monotherapy (once every cycle on day 1 of each cycle).

Timeline

Start

2018-10-16

Primary completion

2021-12-25

Completion

2021-12-25

Drugs

Indications